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Abstract
Background: The present study investigated tumor proliferation in a tumor model using murine ovarian cancer cells with increased 
carbonyl reductase (CR) expression.
Methods: CR cDNA was transfected into murine T-Ag-MOSE ovarian cancer cells by lipofection. CR-transfected cells (CR induction 
group) or empty vector-treated cells (control group) were injected into the backs of 8-week-old nude mice at a concentration of 0.5 × 106 
per 0.2 mL. Subsequent tumor proliferation in both groups was observed for 5 weeks.
Results: The control group showed an increase in tumor volume during the 5 weeks of observation. However, tumor volume in the CR 
induction group increased up to the second week but then decreased continuously until the fifth week of observation. The tumor growth 
curves for the two groups showed a significant difference (Mann-Whitney U test, P , 0.001). Histological and biochemical experi-
ments were performed using tumor tissues isolated in the third week. Necrosis and inflammatory cell infiltration were noted for tumors 
in the CR induction group. Also, the number of apoptotic cells was significantly increased in the CR induction group compared with 
the control group (P , 0.001). Milk fat globule EGF factor 8, an “eat-me” signal for phagocytes such as macrophages, was expressed 
extensively in the tumor cytoplasm and interstitial cells of the CR induction group, and engulfment of apoptotic cells by macrophages 
was observed. Vascular endothelial growth factor expression in tumors was notably decreased in the CR induction group compared with 
the control group.
Conclusion: Increased necrosis due to engulfing of apoptotic cells by phagocytes attracted by increased milk fat globule EGF factor 8 
was considered to be the mechanism of spontaneous tumor regression in the CR induction group.
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Introduction
Ovarian  cancer  is  the  sixth  most  prevalent  cancer 
among women globally, and its annual incidence is 
approximately  200,000.1  Ovarian  cancer  accounts 
for one quarter of reproductive system neoplasms in 
women. It is often not detected until the advanced 
stages, namely stages III or IV, and is the most   frequent 
cause of death among the gynecologic   cancers. The 
current management of advanced   epithelial ovarian 
cancer generally includes cytoreductive surgery fol-
lowed by combination chemotherapy. A combination 
of paclitaxel with a platinum analog can achieve a 
remission rate of over 70% for ovarian cancer,2 but 
recurrence  remains  high.  The  5-year  survival  rate 
remains  at  about  50%,3  and  an  estimated  130,000 
deaths  occur  from  ovarian  cancer  per  year  world-
wide.1 Because anticancer agents alone are not suf-
ficiently  effective,  development  of  other  agents, 
including molecularly targeted drugs, is necessary.
Clofibric acid, a peroxisome proliferator-activated 
receptor α ligand commonly used for the treatment of 
hyperlipidemia, may be one of the candidates for this. 
Our previous in vivo and in vitro studies have dem-
onstrated that clofibric acid has an antitumor effect 
comparable  with  that  of  cisplatin  against  human 
ovarian cancer.4 Because administration of clofibric 
acid in cancer-bearing animals induced a significant 
decrease in prostaglandin (PG) E2 concentration in 
serum and ascitic fluid and a remarkable increase in 
carbonyl reductase (CR) expression, we inferred that 
CR expression is the core factor in clofibric acid treat-
ment, which induced a decrease in PGE2, then caused 
tumor shrinkage due to inhibition of angiogenesis and 
induction of apoptosis.4 CR is present in a variety of 
organs, and its primary function is to control fatty 
acid metabolism.5 CR is also referred to as PGE29 
reductase, and its other important function is convert-
ing PGE2 to PGF2α.6 In order to prove this hypothesis, 
we transfected ovarian cancer cells with an increased 
CR expression vector and investigated the effects of 
CR on the proliferation process in vivo.
Materials and Methods
Cell line and cell culture
T-Ag-MOSE,  established  by  introduction  of  SV40 
large T antigen DNA into C3H/He mouse ovarian 
surface epithelium and could be transfected cDNA 
with great efficiency,7 was obtained from the Health 
Science  Research  Resources  Bank  (Osaka,  Japan). 
Inoculation of T-Ag-MOSE cells onto the back region 
of nude mice can produce xenografted solid tumors.4 
The  cell  line  was  grown  in  Dulbecco’s  Modified 
Eagle  Medium  supplemented  with  10%  fetal  calf 
serum at 37°C in a water-saturated atmosphere with 
5% CO2/95% air.
Transfection
T-Ag-MOSE  cells  were  plated  into  24-well  plates 
and cultured to 60%–80% confluency in Dulbecco’s 
  Modified Eagle Medium containing 10% fetal calf 
serum. Full-length cDNA coding for mouse CR1 was 
ligated into the pBabe Puro expression vector to gener-
ate a CR expression vector.8 Then, 10 µg of the coding 
plasmid was transfected into T-Ag-MOSE cells using 
the GenePorter transfection reagent (Gene   Therapy 
Systems,  San  Diego,  CA)  in  accordance  with  the 
manufacturer’s recommendations. The vector without 
CR1 cDNA was used as the control. Transfected cells 
were cultured in Dulbecco’s Modified Eagle Medium 
with  10%  fetal  calf  serum  containing  1.5  mg/mL 
puromycin for 48 hours. We confirmed expression of 
the CR construct using Western blotting.4
Animal experimentation
The  animal  experiments  were  conducted  in  accor-
dance with the guidelines for animal experimentation 
of Hirosaki University. Eight-week-old female Balb/c 
nu/nu mice were used in this study. All mice were 
group-housed  in  plastic  cages  with  stainless-steel 
grid tops in an air-conditioned room in the Institute 
for Animal Experiments of Hirosaki University, on a 
12-hour light-dark cycle, and fed with water and food 
ad libitum.
Cancer-bearing mouse model
CR-transfected  or  control  T-Ag-MOSE  cells 
(0.5 × 106 cells) in 0.2 mL of Dulbecco’s Modified 
Eagle  Medium  were  inoculated  subcutaneously  on 
the back region of the nude mice. All the mice were 
numbered,  housed  separately,  and  examined  twice 
weekly for tumor development. The tumor dimen-
sions were measured twice weekly using a caliper, 
and tumor volume was calculated using the equation 
V (mm3) = A × B2/2, where A is the largest diameter 
and B is the smallest diameter.9 Tumors were isolated 
from selected mice of both groups in the third week Carbonyl reductase and spontaneous tumor regression
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of  observation,  and  examined  pathologically  and 
biochemically.
Apoptosis
Apoptosis was measured on tissue sections by the termi-
nal deoxyribonucleotidyl transferase (TdT)-  mediated 
dUTP-biotin  nick  end  labeling  (TUNEL)  assay  as 
described by Gavrieli et al10 with some   modifications. 
Briefly, 6 µm sections were stripped from proteins by 
incubation with 10 mg/mL proteinase K for 15 min-
utes  and  immersed  in  H2O2  0.3%  in  methanol  for 
15 minutes to block the endogenous peroxidase. The 
sections were then incubated in TdT buffer mixture 
(200 mM potassium cacodylate, 25 mM Tris-HCl, pH 
6.5, 0.25 mg/mL bovine serum albumin, 1 mM CoCl2, 
0.01 mM biotin-dUTP, 520 U/mL TdT) at 37°C for 
one hour. After rinsing in phosphate-buffered saline, 
the sections were exposed to avidin-biotin-peroxidase 
complex  (Vecta  Laboratories,  Burlingame,  CA)  at 
37°C for 30 minutes. Cells undergoing apoptosis were 
visualized  with  diaminobenzidine  (Sigma-Aldrich, 
St Louis, MO). TUNEL-positive cells per 0.75 mm2 
were counted under a high-power field. Three fields 
were counted per tumor, and the average was taken as 
the frequency of apoptotic cells of each tumor.
Immunohistochemistry
Six  micron  sections  of  formalin-fixed  and 
paraffin-embedded  tissue  specimens  were  stained 
by an established method, as described previously.11 
  Sections were incubated with antibodies specific for 
CR12 and MFG-E8 (Santa Cruz Biotechnology, Santa 
Cruz, CA) for 2 hours. Slides were incubated with 
appropriate  biotinylated  species-specific  second-
ary antibodies for 30 minutes and then exposed to   
avidin-biotin-peroxidase complex. Sections were 
treated with 0.02% diaminobenzidine as a chromogen, 
and counterstained with hematoxylin.
Western blot analysis
Cell lysates (50 µg protein) were prepared from tumor 
tissues,  electrophoresed  through  a  12.5%  sodium 
dodecyl sulfate polyacrylamide gel, and blotted as 
described  previously.13  The  protein  concentration 
was determined using Bradford’s method. The blots 
were  probed  with  the  following  diluted  antibodies 
for 2 hours: CR at 1:1000, cleaved caspase-3 (Santa 
Cruz  Biotechnology)  at  1:1000,  milk  fat    globule 
EGF   factor 8 (MFG-E8) at 1:1000, mouse   vascular 
endothelial growth factor (VEGF) 164 (R&D Sys-
tems,    Minneapolis,  MN)  at  1:500,  and  β-actin 
(  Sigma-Aldrich) at 1:2000. The membranes were then 
incubated for one hour with the appropriate biotiny-
lated  secondary  antibodies,  transferred  to  avidin-
  biotin-peroxidase complex reagent, and incubated in 
this solution for 30 minutes. Diaminobenzidine was 
used as a substrate. Quantification of the results was 
performed by scanning the membrane with Photoshop 
software (version 5.5, Adobe Systems) followed by 
densitometry with the public domain software, NIH 
Image, version 1.62.
Double fluorescence staining  
for detection of apoptotic cells  
and macrophages
Six  micron  sections  were  stripped  from  proteins 
by  incubation  with  10  mg/mL  proteinase  K  for 
15   minutes. The sections were then incubated in TdT 
mixture buffer at 37°C for one hour and in TB buf-
fer at room temperature for 15 minutes, and exposed 
to  the  blocking  solution  at  room  temperature  for 
10 minutes to block the nonspecific reaction. After 
being rinsed in phosphate-buffered saline, the sections 
were incubated with the antibody specific for mouse 
macrophage  (Novocastra  Laboratories,  Newcastle 
upon Tyne, UK) at room temperature for 30 minutes 
and then with FITC-labeled streptavidin at 37°C for 
30 minutes. After being rinsed in phosphate-buffered 
saline, the sections were incubated with antimouse IgG 
Alexa Fluor 555 (Invitrogen) at room temperature for 
one hour. The sections were then counterstained with 
DNA dye 4,6-diamidino-2-phenylindole (DAPI) and 
the results were viewed using fluorescence microscopy. 
Here, proteinase K, TdT mixture buffer, TB buffer, 
the blocking solution, and FITC-labeled streptavidin 
in the Mebstain apoptosis kit II (MBL International, 
Woburn, MA) were used.
Statistical analysis
Differences in tumor volume between the control and 
CR induction groups were analyzed using the one-
tailed Student’s t-test. The significance of the differ-
ence in the frequency of apoptotic cells and expression 
of MFG-E8 between the two groups was also carried 
out using the Student’s t-test. A result was deemed to 
be statistically significant at P , 0.05.Wang et al
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Results
Spontaneous regression of tumors  
with increased Cr expression
Tumor volume was measured in five mice from each 
group.  Tumor  volume  continued  to  increase  in  the 
mice in which T-Ag-MOSE cells without CR had been 
injected (control group, Figure 1). However, it started to 
decrease spontaneously after the second week of obser-
vation in mice into which CR-transfected T-Ag-MOSE 
cells had been injected (CR induction group, Figure 1). 
A significant difference was observed in tumor vol-
ume between the control group and the CR induction 
group from the second week of observation (Fig. 1). 
The experiment was repeated three times, producing 
similar  results.  Figure  2  shows    hematoxylin-eosin 
staining of tumor tissues isolated in the third week of 
observation. Tumor cells were densely packed in tumor 
tissues of the control group, but were sparse in tissues 
of the CR induction group. Large portions of cells were 
also necrotic in the CR induction group. Coagulative 
necrosis with inflammatory cells was observed around 
the tumor tissue (Fig. 2B).
VegF expression in Cr induction  
group tumors
Expression of CR is known to be negatively corre-
lated with that of VEGF, an angiogenesis factor.4 An 
analysis of VEGF expression in tumors of both the 
control group and the CR induction group revealed a 
notable decrease in VEGF in the CR induction group 
(Fig. 3). However, there was no significant difference 
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Figure  1.  Changes  in  tumor  volume  in  control  (n  =  5)  and  carbonyl 
reductase induction (n = 5) groups.
notes:  Tumor  volume  spontaneously  decreased  in  the  carbonyl 
reductase induction group after the second week of observation. Tumor 
growth of the two groups showed a significant difference (Student’s t-test, 
*P , 0.001). results are shown as the mean ± standard deviation.
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Figure 2. hematoxylin-eosin staining of tumor tissue isolated in the third 
week of observation. (A) Tumor from control group and (B) tumor from 
carbonyl reductase induction group.
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in microvessel density identified with the anti-CD31 
antibody  using  immunostaining  in  tumor  tissues 
between the CR induction and control groups (data 
not shown). Thus, there has not been enough evidence 
to show a decrease in angiogenesis in tumors of the 
CR induction group.
Comparison of apoptosis in tumor tissue
The  expression  of  apoptotic  cells  in  tumors  was 
  evaluated using the TUNEL method in the third week 
of observation. To evaluate the extent of   apoptosis in 
tumor tissue, apoptotic cells were stained by the TUNEL 
method, and TUNEL-positive cells per 0.75 mm2 were 
counted in a high power field.   Frequency of the inci-
dence  of TUNEL-positive  cells  (number/mm2)  was 
10.1 ± 3.0 for the control group (n = 5) and 28.7 ± 4.1 
for the CR induction group (n = 5, Figure 4A). The 
incidence of apoptotic cells was significantly higher 
in the CR induction group than in the control group 
(Fig. 4A, P , 0.001). To examine whether the expres-
sion of caspase-3, which becomes activated during 
apoptosis, in tumors in the third week of   observation Carbonyl reductase and spontaneous tumor regression
Clinical Medicine Insights: Oncology 2012:6  111
is  altered,  caspase-3  expression  was  evaluated  by 
Western  blotting.  This  analysis  revealed  that  cas-
pase-3 expression increased by 3.2-fold in CR induc-
tion tumors compared with the controls (Fig. 4B).
Comparison of eat-me signal expression 
in tumor tissue
Eat-me signals on apoptotic cells are known to attract 
inflammatory cells such as macrophages at the time 
of  apoptosis.  MFG-E8,  an  eat-me  signal,  binds  to 
apoptotic cells and attracts macrophages. An assay of 
MFG-E8 expression in tumors isolated from the con-
trol group and from the CR induction group revealed 
significantly  higher  MFG-E8  expression  in  tumors 
in  the  CR  induction  group  (Fig.  5A).  In  addition, 
immunohistochemical  staining  for  investigation  of 
the localization and expression of MFG-E8 showed 
that MFG-E8 was absent in tumors from the control 
group  but  was  extensively  expressed  in  the  tumor 
cytoplasm and interstitial cells in tumors of the CR 
induction group (Fig. 5B). Double fluorescence stain-
ing of tumors isolated from the CR induction group 
showed engulfment of apoptotic cells by macrophages 
(Fig.  6).  These  findings  suggested  that  apoptosis 
occurred frequently in tumors of the CR induction 
group and that necrosis was induced due to phagocy-
tosis (phagocytes such as macrophages are attracted 
to MFG-E8 and capture cancer cells).
Discussion
The findings of the present study clearly demonstrate 
that tumors containing cells with increased CR expres-
sion undergo spontaneous regression. This spontane-
ous regression was considered to occur as a result of 
apoptosis as well as necrosis. As shown in Figure 5, 
MFG-E8  expression  was  significantly  increased  in 
tumors containing cells with increased CR expres-
sion, suggesting that the notable increase in necrosis 
in tumors containing cells with increased CR expres-
sion was induced by engulfment of apoptotic cells by 
phagocytes, such as macrophages.
It is generally accepted that MFG-E8 is secreted 
from cells that have synthesized it, and then binds to 
the surface of apoptotic cells.14 However, the present 
study raises the issue of whether the MFG-E8 detected 
is synthesized and secreted by CR-transfected cells or 
by the host’s leukocytes stimulated by CR-expressing 
cancer cells, given that localization of CR, MFG-E8, 
and  leukocytes  was  not  confirmed  in  consecutive 
  sections. Localization of MFG-E8 seen in Figure 5 
demonstrates that MFG-E8 is present in both cancer 
cells and interstitial cells, indicating either or both 
could  be  possible.  Wakui  et  al  reported  increased 
apoptosis and occurrence of necrosis in ovarian can-
cer  tissue  treated  with  photodynamic  therapy,  and 
demonstrated immunohistochemically that MFG-E8 
expression was localized in the nuclei and cell mem-
branes of cancer cells.9 These findings support the 
hypothesis that MFG-E8 synthesized in cancer cells 
is secreted into the surrounding tissues.
There remains the issue of the difference in host 
response between tumors containing cells with high 
CR expression and tumors containing control cells. 
The  results  of  the  present  study  seem  to  suggest 
that this is because apoptosis in tumors containing 
CR-  expressing cells induce MFG-E8 secretion that, 
in  turn,  induces  phagocytosis  by  attracting  mac-
rophages and other phagocytes. However, necrosis of 
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Figure 3. relationship between vascular endothelial growth factor and 
carbonyl  reductase  expression  in  carbonyl  reductase  induction  group 
and control group.
notes: Western blot using the proteins from tumor tissues of both groups 
revealed a notable decrease in vascular endothelial growth factor in the 
carbonyl reductase induction group. Pictures shown are representative 
of the tumors in each group.Wang et al
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Figure 4. (A) Comparison of frequency of apoptotic cells. (B) Altered expression of caspase-3 in carbonyl reductase induction tumors and controls.
notes: Frequency of incidence of TUneL-positive cells (number/mm2) was 10.1 ± 3.0 for the control group (n = 5) and 28.7 ± 4.1 for the carbonyl reductase 
induction group (n = 5), which was significantly different. *P , 0.001 versus control group. results are shown as the mean ± standard deviation. Caspase-3 
expression increased by 3.2-fold in carbonyl reductase induction tumors. Densitometric values represent the actin-corrected means of five blots. Blots 
shown are from one representative experiment of five.
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CR-  expressing cells may also be due to secretion of a 
  factor   similar to tumor necrosis factor alpha (TNFα) by 
macrophages that are attracted to an eat-me   signal-like 
substance secreted by CR-expressing cells. TNFα is 
a homotrimer of 17 kDa protein subunits, and is a 
potent mediator of diseases and metabolic functions.15 
TNFα induces necrosis in cancer cells in vivo, and has 
cytolytic effects on cancer cells in vitro. Maslinic acid, 
which is both an antioxidant and anti-  inflammatory 
substance, has been reported to inhibit pancreatic can-
cer  cell  growth  significantly  by  activating TNFα.16 
Maslinic acid achieves this by significantly decreas-
ing the expression of genes associated with the NF-κB 
signal pathway, such as cyclin-D1, cyclo-oxygenase-2, 
survivin, matrix metalloproteinase-9, and VEGF, that 
are  involved  with  cell  proliferation,  antiapoptosis, Carbonyl reductase and spontaneous tumor regression
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Figure 6. Double fluorescence staining of apoptotic cells and macrophages.
notes: Phagocytosis (arrows) is shown in tumors of the carbonyl reductase induction group. Asterisk shows a macrophage (stained in red) is engulfing 
cell with fragmented nuclei (apoptotic cell, stained in green).
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Figure 5. (A) Comparison of MFg-e8 expression in tumors (Western blotting). (B) Localization of MFg-e8 expression (immunohistochemical staining).
notes: expression of MFG-E8 was significantly higher in the carbonyl reductase induction group than in the control group. Signal density means densitomet-
ric values that represent the actin-corrected means of three blots. *P , 0.002 versus control. results are shown as the mean ± standard deviation.  MFg-e8 
was expressed in tumor cells and interstitial cells in the carbonyl reductase induction group. however, MFg-e8 was not detected in the control group.
infiltration, and   angiogenesis.10   Therefore, a thorough 
investigation of the TNFα signaling pathway may be 
necessary in cells into which CR, which is also both 
an antioxidant and anti-  inflammatory substance, have 
been transfected.
Recently, the exactly opposite evidence concerning 
a crucial role of MFG-E8 in tumor progression have 
been  reported.17,18  While  MFG-E8  promotes  VEGF-
  dependent angiogenesis,17 MFG-E8 regulates the anti-
tumor effect by efficient phagocytosis of apoptotic cells Wang et al
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via induced granulocyte-macrophage colony stimulat-
ing  factor  activity.18 This  complicated  evidence  sug-
gests pleiotropic roles for MFG-E8. Indeed, in breast 
cancers, MFG-E8 is expressed in triple-negative [estro-
gen receptor (-), progesterone receptor (-), erbB2 (-)] 
breast cancers as a target gene of the p63 pathway, 
whereas it exhibits a suppressive function in estrogen 
receptor  (+)  and  erbB2  (+)  breast  cancers.19  In  this 
study,  increased  MFG-E8  in  CR-transfected  tumors 
was related to engulfment of apoptotic cells by phago-
cytes, such as macrophages, resulting in tumor regres-
sion. However, MFG-E8 expression did not correlate 
with either VEGF expression or angiogenesis. Such dif-
ferent functions of MFG-E8 warrant continued study of 
whether MFG-E8 is a tumor promoter or a suppressor.
In a previous study, we found that clofibric acid, a 
peroxisome proliferator-activated receptor α ligand, 
exerts an antitumor effect, partly by increasing CR 
expression in ovarian cancer tissue.4 We also dem-
onstrated  that  increased  CR  expression  in  tumors 
achieved  tumor  regression  by  inhibiting  angiogen-
esis and inducing apoptosis.4 The present study also 
showed  that  VEGF  expression  in  tumors  contain-
ing CR-transfected cells was decreased in compari-
son with that in control tumors. However, there was 
no  significant  difference  in  microvessel  density  in 
tumor tissue between the two groups. Thus, there is 
enough evidence to show a decrease in angiogenesis 
in tumors of the CR induction group. Further study 
would be necessary to elucidate the inverse relation-
ship between expressions of VEGF and CR in spon-
taneous tumor regression.
Clofibric acid is the only drug known to increase CR 
expression in tumors. The findings of the present study 
have  strengthened  the  evidence  that  CR  expression 
in a tumor induces an antitumor effect. This suggests 
clofibric acid is a promising substance for molecularly 
targeted drugs that could increase CR expression in 
tumor tissue. Clinical trials should be urgently planned 
to establish the antitumor effect of clofibric acid, a pri-
mary component of antihyperlipidemic agents.
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